PGAM5 and neoplasm: Correlation analysis of both the testing cohort (TMUCH patients) and validation cohort (SYSUCC patients) demonstrated that PGAM5 overexpression was positively correlated with more advanced clinical stages and tumor relapses (p < 0.05, Table S1).